The answer to that really stems from what we've learned in the course of the pandemic about the need to ensure we have the infrastructure in Canada to be able to fully synthesize and be self-sufficient with respect to vaccine production, and, in reality, a number of other agents that would be required for other therapeutic interventions over time.
The investments that are in the process of being made at this time—and, again, I refer back to the biomanufacturing initiative but also specifically to the CIHR and the tri-agency's role in this—have been very much to begin to design the programs that will start at the very early part of this to ensure that, for the actual ideas that are synthesized here in Canada, the research is done within Canada, the IT is protected and the partnerships with industry are in place. However, when it comes to the point of scaling up and being able to do the actual synthesis, this is an area where our colleagues at ISED have been doing massive investments in order to ensure we have the capacity for fill and finish.
The lesson learned from the pandemic has been that Canada needs to have a steady state of capacity that will allow us to ensure we can produce vaccines or other therapeutics without having to rely on other countries to do so. It is the pipeline that needs to be constructed, and the resources have been provided to us to start the foundations of that.